56 results
Page 3 of 3
8-K
EX-99.2
qgkfep
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
8-K
EX-99.3
9b170icqry5eehw4q7hl
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
10-Q
arcu hit4k8n66f5uq6a
9 May 19
Quarterly report
7:13am
DEF 14A
4xc nnm8k3p
26 Apr 19
Definitive proxy
5:00pm
10-K
EX-10.11
864m 3gmk3y
28 Feb 19
Annual report
1:08pm
10-K
pa2jwj utxfmpz7p2d
28 Feb 19
Annual report
1:08pm
10-K
EX-10.12
exe8mat
28 Feb 19
Annual report
1:08pm
424B5
j04kcapm95x1e1y
25 Jan 19
Prospectus supplement for primary offering
8:01am
424B5
l33cm p4e6z
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
pbe1r3goo3wp
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
F-3
pmm4b4ltgzqwym3ud
12 Oct 18
Shelf registration (foreign)
5:24pm
20-F
EX-4.2
sjh9kseuvp
15 Mar 18
Annual report (foreign)
12:00am
20-F
0knxs9iapzfjd4
15 Mar 18
Annual report (foreign)
12:00am
424B4
ty9eq1u1si9ygbw
22 Jan 18
Prospectus supplement with pricing info
12:00am